Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for TARS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 3.302M
March 31, 2026 1.204M
December 31, 2025 2.312M
September 30, 2025 2.562M
June 30, 2025 1.952M
March 31, 2025 136.56M
December 31, 2024 2.927M
September 30, 2024 0.639M
June 30, 2024 42.32M
March 31, 2024 108.77M
December 31, 2023 19.76M
September 30, 2023 104.89M
June 30, 2023 0.51M
March 31, 2023 5.013M
Date Value
December 31, 2022 0.264M
September 30, 2022 -0.136M
June 30, 2022 74.73M
March 31, 2022 19.12M
December 31, 2021 -0.074M
September 30, 2021 0.075M
June 30, 2021 0.001M
March 31, 2021 0.019M
December 31, 2020 91.76M
September 30, 2020 39.90M
June 30, 2020 0.134M
March 31, 2020 -0.027M
December 31, 2019 58.44M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Structure Therapeutics, Inc. 2.091M
Alumis, Inc. 12.63M
Veradermics, Inc. 442.70M
ANI Pharmaceuticals, Inc. -4.647M
Corcept Therapeutics, Inc. -2.037M